Peptide analogues of a T-cell epitope of ricin toxin A-chain prevent agonist-mediated human T-cell response

International Immunology

Volumn 17, Issue 4, 2005, Pages 365-372

  Castelletti, D ^a   Colombatti, Marco ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Altered peptide ligands; Antagonists; Immune modulation; Ricin toxin A chain; T cell epitopes

Indexed keywords

ALANINE; EPITOPE; HLA DR ANTIGEN; IMMUNOTOXIN; NEUTRALIZING ANTIBODY; PEPTIDE DERIVATIVE; RICIN; T LYMPHOCYTE RECEPTOR;

ALLELE; AMINO ACID SUBSTITUTION; ANTIBODY PRODUCTION; ARTICLE; CELL CLONE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOMODULATION; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; WILD TYPE;

AMINO ACIDS; DOWN-REGULATION; EPITOPES, T-LYMPHOCYTE; HUMANS; LYMPHOCYTE ACTIVATION; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; RICIN; T-LYMPHOCYTES;

EID: 17644373019     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/dxh216     Document Type: Article

References (35)

1. Engert, A., Sausville, E. A. and Vitetta, E. 1998. The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma. Curr. Top. Microbiol. Immunol. 234:13.
2. Colombatti, M. 2002. Ricin A: structure, function and its clinical applications. In Lazarovici, P. and Lorberboum-Galski, H., eds, Chimeric Toxins: Mechanisms of Action and Therapeutic Applications, pp. 37-85. Taylor and Francis, London and New York.
3. Kreitman, R. J. 1999. Immunotoxins in cancer therapy. Curr. Opin. Immunol. 11:570.
4. Antin, J. H., Bierer, B. E., Smith, B. R. et al. 1991. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 78:2139.
5. Stoudemire, J. B., Mischak, R., Foxall, C., Harkonen, W. S., Del Rio, M. and Spitler, L. E. 1990. The effects of cyclophosphamide on the toxicity and immunogenicity of ricin A chain immunotoxin in rats. Mol. Biother. 2:179.
6. Jin, F. S., Youle, R. J., Johnson, V. G. et al. 1991. Suppression of the immune response to immunotoxins with anti-CD4 monoclonal antibodies. J. Immunol. 146:1806.
7. Tommasi, M., Castelletti, D., Pasti, M. et al. 2001. Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones. Clin. Exp. Immunol. 125:391.
8. Frasca, L., Del Porto, P., Tuosto, L. et al. 1999. Hypervariable region 1 variants act as TCR antagonists for hepatitis C virus-specific CD4+ T cells. J. Immunol. 163:650.
9. Sloan-Lancaster, J. and Allen, P. M. 1996. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu. Rev. Immunol. 14:1.
10. Adorini, L. 1993. Selective inhibition of T cell responses by protein and peptide-based immunotherapy. Clin. Exp. Rheumatol. 11 (Suppl. 8):S41.
11. Ruiz, P. J., Garren, H., Hirschberg, D. L. et al. 1999. Microbial epitopes act as altered peptide ligands to prevent experimental autoimmune encephalomyelitis. J. Exp. Med. 189:1275.
12. Faber-Elmann, A., Paas-Rozner, M., Sela, M. and Mozes, E. 1998. Altered peptide ligands act as partial agonists by inhibiting phospholipase C activity induced by myasthenogenic T cell epitopes. Proc. Natl Acad. Sci. USA 95:14320.
13. Kappos, L., Comi, G., Panitch, H. et al. 2000. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The altered peptide ligand in relapsing MS Study Group. Nat. Med. 6:1176.
14. Kim, H. J., Antel, J. P., Duquette, P., Alleva, D. G., Conlon, P. J. and Bar-Or, A, 2002. Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. Clin. Immunol. 104:105.
15. Gjertsen, D. W. and Terasaki, P. I. Estimation of HLA-A, -B, -DR haplotype frequencies in five racial groups represented in the NMDP donor file, In HLA 1998, pp. 18-37. American Society for Histo-compatibility and Immunogenetics, Lenexa, Kansas. Lenexa, KS.
16. Merrifield, R. B. 1969. Solid-phase peptide synthesis. Adv. Enzymol. Relat. Areas Mol. Biol. 32:221.
17. Pera, C., Delfino, L., Morabito, A. et al. 1997. HLA-A typing: comparison between serology, the amplification refractory mutation system with polymerase chain reaction and sequencing. Tissue Antigens 50:372.
18. Delfino, L., Morabito, A., Longo, A. and Ferrara, G. B. 1998. HLA-C high resolution typing: analysis of exons 2 and 3 by sequence based typing and detection of polymorphisms in exons 1-5 by sequence specific primers. Tissue Antigens 52: 251.
19. Robinson, J., Malik, A., Parham, P., Bodmer, J. G. and Marsh, S. G. 2000. IMGT/HLA database - a sequence database for the human major histocompatibility complex. Tissue Antigens 55:280.
20. Valitutti, S,, Muller, S., Cella, M., Padovan, E. and Lanzavecchia, A. 1995. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375:148.
21. Monzingo, A. F., Collins, E. J., Ernst, S. R., Irvin, J. D. and Robertus, J. D. 1993. The 2.5 A structure of pokeweed antiviral protein, J. Mol. Biol. 233:705.
22. Husain, J., Tickle, I. J. and Wood, S. P. 1994. Crystal structure of momordin, a type I ribosome inactivating protein from the seeds of Momordica charantia 1. FEBS Lett. 342:154.
23. Jung, C., Kalbus, M., Fleckenstein, B., Melms, A., Jung, G. and Wiesmuller, K. H. 1998. New ligands for HLA DRB1*0301 by random selection of favourable amino acids ranked by competition studies with undecapeptide amide sublibraries. J. Immunol. Methods 219:139.
24. Kim, B. S., Bahk, Y. Y., Kang, H. K. et al. 1999. Diverse fine specificity and receptor repertoire of T cells reactive to the major VP1 epitope (VP1230-250) of Theiler's virus: V beta restriction correlates with T cell recognition of the c-terminal residue. J. Immunol. 162:7049.
25. Viola, A. and Lanzavecchia, A. 1996. T cell activation determined by T cell receptor number and tunable thresholds. Science 273:104.
26. De Magistris, M. T., Alexander, J., Coggeshall, M. et al. 1992. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 68:625.
27. Madrenas, J. 1999. Differential signalling by variant ligands of the T cell receptor and the kinetic model of T cell activation. Life Sci. 64:717.
28. Bachmann, M. F., Salzmann, M., Oxenius, A. and Ohashi, P. S. 1998. Formation of TCR dimers/trimers as a crucial step for T cell activation. Eur. J. Immunol. 28:2571.
29. Bachmann, M. F., Speiser, D. E., Zakarian, A. and Ohashi, P. S. 1998. Inhibition of TCR triggering by a spectrum of altered peptide ligands suggests the mechanism for TCR antagonism. Eur. J. Immunol. 28:3110.
30. Valitutti, S., Dessing, M., Aktories, K., Gallati, H. and Lanzavecchia, A. 1995. Sustained signaling leading to T cell activation results from prolonged T cell receptor occupancy. Role of T cell actin cytoskeleton. J. Exp. Med. 181:577.
31. Castelletti, D., Fracasso, G., Righetti, S. et al. 2004. A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin. Clin. Exp. Immunol. 136: 365.
32. Shirai, M., Arichi, T., Chen, M. et al. 1999. T cell recognition of hypervariable region-1 from hepatitis C virus envelope protein with multiple class II MHC molecules in mice and humans: preferential help for induction of antibodies to the hypervariable region. J. Immunol. 162:568.
33. Vanderlugt, C. L., Neville, K. L., Nikcevich, K. M., Eagar, T. N., Bluestone, J. A. and Miller, S. D. 2000. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J. Immunol. 164:670.
34. Yin, L., Yu, M., Edling, A. E. et al. 2001. Pre-emptive targeting of the epitope spreading cascade with genetically modified regulatory T cells during autoimmune demyelinating disease. J. Immunol. 167:6105.
35. Yeung, V. P., Chang, J., Miller, J., Barnett, C., Stickler, M. and Harding, F. A. 2004. Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope. J. Immunol. 172:6658.